BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Hemophilia Alliance - ECPv6.3.7//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://hemoalliance.org
X-WR-CALDESC:Events for Hemophilia Alliance
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/New_York
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20230312T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20231105T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20231107T140000
DTEND;TZID=America/New_York:20231107T150000
DTSTAMP:20260404T075637
CREATED:20231023T165946Z
LAST-MODIFIED:20231023T165946Z
UID:45791-1699365600-1699369200@hemoalliance.org
SUMMARY:🟥 Member Webinar : Hemophilia Alliance Hosts - A Webinar from Pfizer - Case Studies of Using BeneFix® (Coagulation Factor IX [Recombinant]) in Different Hemophilia B Patient Populations in an Evolving Treatment Landscape – Is There More to the Story?
DESCRIPTION:Date: Tuesday\, November 7\, 2023\nTime: 2:00pm – 3:00pm ET \n\n \nTITLE:\nCase Studies of Using BeneFix® (Coagulation Factor IX [Recombinant]) in Different Hemophilia B Patient Populations in an Evolving Treatment Landscape – Is There More to the Story? \nSPEAKER:\n\nDoris Quon\, MD \nMedical Director of the Orthopaedic Hemophilia Treatment Center at the Luskin Orthopaedic Institute for Children in Los Angeles\, California
URL:https://hemoalliance.org/alliance-events/a-webinar-from-pfizer-case-studies-of-using-benefix-coagulation-factor-ix-recombinant-in-different-hemophilia-b-patient-populations-i/
CATEGORIES:Members Only,Webinar
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20231109T130000
DTEND;TZID=America/New_York:20231109T140000
DTSTAMP:20260404T075637
CREATED:20230921T185243Z
LAST-MODIFIED:20230921T185243Z
UID:45676-1699534800-1699538400@hemoalliance.org
SUMMARY:🟥 Member Webinar : Hemophilia Alliance Hosts - A Discussion from Genentech About Subcutaneous Prophylaxis Treatment for Hemophilia A
DESCRIPTION:Date: Thursday\, November 9\, 2023\nTime: 1:00pm – 2:00pm ET \n\n \nTITLE:\nLearn More About Subcutaneous Prophylaxis Treatment for Hemophilia A:  A Discussion on the Latest Data and Patient Management \nDESCRIPTION:\nPlease join us for an engaging webinar led by Ketna Mistry\, MD who will be sharing information on patients with hemophilia A with a subcutaneous prophylaxis including the latest clinical data.  Ther presentation will include pivotal efficacy and safety data\, joint health data\, data in infants\, and an overview of real-world experience.  Be sure to bring your questions to have them answered during the Q&A following the program! \nSPEAKER:\n\nKetna Mistry\, MD \nMedical Director\, Hematology & Rare Blood Disorders\, U.S. Medical Affairs; Genentech \nDr. Mistry has 25 years of experience in her medical career\, as a physician caring for patients and teacher at Emory University\, a researcher at CDC\, and currently as a medical director at Genentech.  She completed medical school at Tulane University and graduated with honors from UCLA for her bachelor’s degree in psychobiology. She completed her internship and residency in pediatrics at University of Texas in Houston.  She is passionate about teaching and sharing information so that patients and providers can make the best informed decision for their care.
URL:https://hemoalliance.org/alliance-events/a-discussion-from-genentech-about-subcutaneous-prophylaxis-treatment-for-hemophilia-a/
CATEGORIES:Members Only,Webinar
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20231110
DTEND;VALUE=DATE:20231113
DTSTAMP:20260404T075637
CREATED:20230430T195240Z
LAST-MODIFIED:20230816T203938Z
UID:42903-1699574400-1699833599@hemoalliance.org
SUMMARY:🟥 Member Event : Physicians & Business Administrators Meeting
DESCRIPTION:Location: Redondo Beach\, California\nVenue: The Portofino Hotel & Marina \n\nPlease contact Theresa Parker with any questions regarding this registration at theresa@hemoalliance.org or 727.688.2568. \n\nDRAFT AGENDA \nFriday: 8 am to 5 pm\nFor Business Administrators \n\nAlliance Services – an overview of what is offered by Hemophilia Alliance\n340B Refresher – Basic overview with answers to targeted questions\nUnderstanding Medicaid & Medicare – A look at the public payers and changes\nHANS – Why it’s important to have payer contracts\nWhy we need National Patient Org\nAdvocacy – Threats and Opportunities for HTCs\nUnderstanding GPO contracts\nRunning an HTC pharmacy – Having a Strategic Plan\nLegal Discussion – Understanding the challenges\n\n6 pm – Dinner \nSaturday: 8 am to 12:30 pm\nBusiness Course \nSunday: 8 am to 12:30 pm\nFor Clinical Providers \n\nStrengths: Leadership – How to work within an HTC\nWeakness: Relationships – How to work within a larger institute\nOpportunities: Risk – Going Independent\nThreats: Planning – Strategic Plan
URL:https://hemoalliance.org/alliance-events/2023-physicians-business-administrators-meeting/
LOCATION:The Portofino Hotel & Marina\, Redondo Beach\, 260 Portofino Way\, Redondo Beach\, CA\, 90277\, United States
CATEGORIES:Members Only
ORGANIZER;CN="Jeff Blake":MAILTO:jeff@hemoalliance.org
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20231113T130000
DTEND;TZID=America/New_York:20231113T140000
DTSTAMP:20260404T075637
CREATED:20231107T161931Z
LAST-MODIFIED:20231107T161931Z
UID:45954-1699880400-1699884000@hemoalliance.org
SUMMARY:🟥 Member Webinar : Hemophilia Alliance Hosts - A webinar on Hemgenix Real World Learnings from CSL Behring
DESCRIPTION:Date: Monday\, November 13\, 2023\nTime: 1:00pm – 2:00pm ET \n\n \nTITLE:\nHemgenix Real World Learnings \nSPEAKER:\n\nVidhi Desai\, MD \nSenior Medical Director\, Coagulation\nNorth America Medical Affairs \nVidhi Desai joined CSL Behring in 2018 as Therapeutic Area Head\, Director Medical Affairs for Coagulation Products in North America\, providing strategic and tactical medical leadership for Idelvion®\, Afstyla®  and Humate-P®\, contributing to key operational and cross-functional projects as a member of the Medical Affairs leadership team. \nPrior to joining CSL Behring\, Vidhi worked as an attending hematologist at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell\, focusing primarily on benign hematologic disorders. \nVidhi earned her Doctor of Medicine at New York Medical College and completed her internal medicine and hematology/oncology training at Rutgers Robert Wood Johnson Medical School in New Brunswick\, NJ.
URL:https://hemoalliance.org/alliance-events/a-webinar-on-hemgenix-real-world-learnings-from-csl-behring/
CATEGORIES:Members Only,Webinar
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20231117T130000
DTEND;TZID=America/New_York:20231117T140000
DTSTAMP:20260404T075637
CREATED:20231025T210322Z
LAST-MODIFIED:20231025T210322Z
UID:45830-1700226000-1700229600@hemoalliance.org
SUMMARY:🟥 Member Webinar : Hemophilia Alliance Hosts - An Informational Session from Bayer - Clinical review of the Jivi® PROTECT VIII Trial and insights from HEM-POWR: A Real-World Evidence (RWE) Study of Jivi®
DESCRIPTION:Date: Friday\, November 17\, 2023\nTime: 1:00pm – 2:00pm ET \n\n \nTOPIC:\nClinical review of the Jivi® PROTECT VIII Trial and insights from HEM-POWR: A Real-World Evidence (RWE) Study of Jivi® \nOVERVIEW:\nThis session includes key information about Jivi including\, safety and efficacy data from the clinical trials\, step-wise dosing and Jivi RWE Data from HEM-POWR\, a multinational\,open-label\, prospective\, non-interventional\, multicenter cohort study of Jivi®. \nThere will also be a review of the Q4 2023 340B pricing for the Bayer Hemophilia A portfolio under the Hemophilia Alliance Contract. \nTARGET AUDIENCE:\nAll HTC Staff \nSPEAKER:\n\nMark T. Reding\, MD. \nDirector\, Center for Bleeding and Clotting Disorders\nProfessor of Medicine\, Division of Hematology\, Oncology\, and Transplantation\nUniversity of Minnesota \n\n\n\nFor additional important risk and use information\, please see the full Prescribing Information for Jivi.\nYou are encouraged to report negative side effects or quality complaints of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
URL:https://hemoalliance.org/alliance-events/an-informational-session-from-bayer-clinical-review-of-the-jivi-protect-viii-trial-and-insights-from-hem-powr-a-real-world-evidence-rwe/
CATEGORIES:Members Only,Webinar
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20231127T130000
DTEND;TZID=America/New_York:20231127T140000
DTSTAMP:20260404T075637
CREATED:20231031T175111Z
LAST-MODIFIED:20231031T175452Z
UID:45934-1701090000-1701093600@hemoalliance.org
SUMMARY:🟥 Member Webinar : Hemophilia Alliance Hosts - A webinar from HEMA Biologics - A different treatment option for Inhibitor patients
DESCRIPTION:Date: Monday\, November 27\, 2023\nTime: 1:00pm – 2:00pm ET \n\n \nTITLE:\nA different treatment option for Inhibitor patients \nOBJECTIVE:\nThis presentation will provide an overview of inhibitors and explore the efficacy\, safety\, tolerability\, clinical development\, and reasons to consider a different treatment option. \nTARGET AUDIENCE:\nAll HTC Staff \nSPEAKER:\n\nGuy Young\, MD. \nDirector\, Hemostasis and Thrombosis Center\nDirector\, Clinical Coagulation Laboratory Cancer and Blood Disorders Institute Children’s Hospital Los Angeles\nProfessor of Pediatrics\, University of Southern California Keck School of Medicine
URL:https://hemoalliance.org/alliance-events/a-webinar-from-hemabiologics-a-different-treatment-option-for-inhibitor-patients/
CATEGORIES:Members Only,Webinar
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20231129T130000
DTEND;TZID=America/New_York:20231129T140000
DTSTAMP:20260404T075637
CREATED:20231121T163230Z
LAST-MODIFIED:20231121T163230Z
UID:46010-1701262800-1701266400@hemoalliance.org
SUMMARY:🟥 Member Webinar : Hemophilia Alliance Hosts - A webinar from Takeda - Overview of Adzynma (rADAMTS13) Prescribing Information
DESCRIPTION:Date: Wednesday\, November 29\, 2023\nTime: 1:00pm – 2:00pm ET \n\n \nTITLE:\nOverview of Adzynma (rADAMTS13) Prescribing Information \nOBJECTIVE:\nInform on the new approval and prescribing information of Adzynma indicated for prophylactic and on-demand use for patients with congenital TTP. \nTARGET AUDIENCE:\nHematologists\, NPs\, nurses\, pharmacists \nSPEAKER:\n\nAli Mokdad\, MD\, PhD\, MBA\, Medical Director\, Takeda
URL:https://hemoalliance.org/alliance-events/a-webinar-from-takeda-overview-of-adzynma-radamts13-prescribing-information/
CATEGORIES:Members Only,Webinar
END:VEVENT
END:VCALENDAR